• Vyne Therapeutics entered an exchange agreement to issue pre-funded warrants for 133,290 common shares in exchange for 133,290 common shares.
• Pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share.
• Warrants cap exercise to avoid beneficial ownership above 9.99%, adjustable up to 19.99% with 61 days’ notice.
• Exchange closed July 29, 2026; 2,669,788 common shares outstanding, pre-funded warrants outstanding for 25,914,530 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-088662), on July 30, 2026, and is solely responsible for the information contained therein.